Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Next Previous
Trial Profile

Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APVO 210 (Primary)
  • Indications Plaque psoriasis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics

    • Most Recent Events

    • 03 Oct 2019 Status changed from recruiting to discontinued, according to an Aptevo Therapeutics media release. The decision followed the review of data from the Phase 1 multiple ascending dose (MAD) clinical study of APVO210 in healthy volunteers that suggests that APVO210 would not meet the desired target product profile for future commercialization.
    • 07 Aug 2019 According to an Aptevo Therapeutics media release, with preliminary top-line safety data from an autoimmune-focused bispecific antibody candidate, APVO210, recently showing encouraging results, prompting the initiation of the next stage of this phase I clinical trial-evaluating multiple ascending doses of APVO210.
    • 20 Mar 2019 According to an Aptevo Therapeutics media release, the company has commenced dosing in this trial. The study is expected to enroll a maximum of 64 subjects in the initial SAD dose cohort and up to 40 subjects in the MAD dose cohort.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top